| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| PC9-R52H5 | Rabbit | Human PCSK9 Propeptide & Rabbit Mature PCSK9 (154-686) Protein, His Tag |  |
|
|
| EP-103 | Human | PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair |
|
||
| PC9-H5256 | Human | Human PCSK9 Protein, Fc Tag |  |
|
|
| PC9-H52E4 | Hamster | Hamster PCSK9 Protein, His Tag |  |
|
|
| PC9-C5223 | Cynomolgus | Cynomolgus PCSK9 Protein, His Tag |  |
|
|
| PC9-M82E1 | Mouse | Biotinylated Mouse PCSK9 Protein, Avitag™,His Tag |  |
|
|
| PCA-H5226 | Human | Human PCSK9 (R194A) Protein, His Tag |  |
|
|
| PCY-H5225 | Human | Human PCSK9 (D374Y) Protein, His Tag |  |
|
|
| PC9-C52H2 | Rhesus macaque | Rhesus macaque PCSK9 Protein, His Tag |  |
|
|
| PC9-R52H4 | Rat | Rat PCSK9 Protein, His Tag |  |
|
|
| PCY-H82E7 | Human | Biotinylated Human PCSK9 (D374Y) Protein, Avitag™,His Tag |  |
|
|
| PC9-H82E7 | Human | Biotinylated Human PCSK9 Protein, Avitag™,His Tag (MALS verified) |  |
|
|
| PC9-M5228 | Mouse | Mouse PCSK9 Protein, His Tag |  |
|
|
| PC9-H5223 | Human | Human PCSK9 Protein, His Tag (MALS Verified) |  |
|
|
FACS analysis shows that Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibits LDL uptake in HepG2 cells. The EC50 for this effect is 0.0689-0.3049 μg/mL.
FACS analysis shows that the effect of Human PCSK9 (D374Y), His Tag (Cat. No. PCY-H5225) inhibiting LDL uptake in HepG2 cells was neutralized by Anti-Human PCSK9 antibody. The concentration of PCSK9 used is 5 μg/mL. The EC50 for Anti-Human PCSK9 antibody is 6.816-12.67 μg/mL.
Loaded Human PCSK9, Fc Tag (Cat. No. PC9-H5256) on Protein A Biosensor, can bind Human LDL R, His Tag (Cat. No. LDR-H5224) with an affinity constant of 12.7 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Evolocumab | AMG-145 | Approved | Amgen Inc, Astellas Pharma Inc | 瑞百安, Repatha | Mainland China | Atherosclerosis; Homozygous familial hypercholesterolemia | Amgen Inc | 2015-07-17 | Homozygous familial hypercholesterolemia; Myocardial Infarction; Diabetes Mellitus, Type 2; Atherosclerosis; Hypercholesterolemia; Coronary Artery Disease; Stroke; Heterozygous familial hypercholesterolemia; Coronary Disease; Dyslipidemias; Cardiovascular Diseases; Diabetes Mellitus; Hyperlipoproteinemia Type II; Hyperlipidemias | Details |
| Inclisiran sodium | ALN-PCSsc; KJX839; KJX-839; ALN-60212; PCSK9si | Approved | Alnylam Pharmaceuticals Inc | Leqvio | United States | Atherosclerosis; Heterozygous familial hypercholesterolemia | Novartis Pharma Ag | 2020-12-09 | Plaque, Atherosclerotic; Homozygous familial hypercholesterolemia; Atherosclerosis; Diabetes Mellitus, Type 2; Hypercholesterolemia; Kidney Diseases; Hypolipoproteinemias; Acute Coronary Syndrome; Heterozygous familial hypercholesterolemia; Dyslipidemias; Hyperlipoproteinemia Type II; Diabetes Mellitus; Hyperlipidemias | Details |
| Alirocumab | 316P; REGN-727; SAR-236553 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | 波立达, Praluent | Mainland China | Dyslipidemias; Hypercholesterolemia; Atherosclerosis | Sanofi-Aventis Groupe | 2015-07-24 | Homozygous familial hypercholesterolemia; Atherosclerosis; Hypercholesterolemia; Acute Coronary Syndrome; Heterozygous familial hypercholesterolemia; Dyslipidemias | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Recombinant human anti-PCSK9 monoclonal antibody (Salubris) | SAL003 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias; Hyperlipidemia, Familial Combined | Details |
| CiVi-007 | CiVi-007; LNA-PCSK -9; LNA-PCSK9-GalNac | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Hypercholesterolemia | Details |
| Recombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm) | B1655; B-1655 | Phase 1 Clinical | Tianjin Tasly Pharmaceutical Co Ltd | Hypercholesterolemia | Details |
| PCSK9 modulator (Genekey Biotech) | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Metabolic Diseases; Inflammation | Details | |
| ATH-04 | ATH-04 | Phase 1 Clinical | Affiris | Atherosclerosis | Details |
| Frovocimab | LY-3015014 | Phase 2 Clinical | Eli Lilly And Company | Hypercholesterolemia; Hyperlipidemias | Details |
| SAL-092 | SAL092; SAL-092 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias | Details |
| Anti-PCSK9 monoclonal antibody (Biocad) | Phase 1 Clinical | Biocad | Cardiovascular Diseases | Details | |
| DC-371739 | DC-371739 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Hypercholesterolemia; Dyslipidemias; Hyperlipidemias | Details |
| AZD-8233 | AZD-8233; IONIS-AZ4-2.5-LRx; ION-449 | Phase 2 Clinical | Hypercholesterolemia; Dyslipidemias; Hyperlipidemias; Kidney Failure, Chronic | Details | |
| CVI-LM-001 | CVI-LM-001; CVI-LM001; C-8304 | Phase 2 Clinical | Xiwei'Ai Medicine Technology (Shanghai) Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| NN-6434 | NN-6434 | Phase 1 Clinical | Novo Nordisk A/S | Details | |
| Tafolecimab | IBI-306 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Homozygous familial hypercholesterolemia; Hypercholesterolemia; Heterozygous familial hypercholesterolemia | Details |
| SHR-1209 | SHR-1209 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Hypercholesterolemia; Hyperlipoproteinemia Type V; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
| Ongericimab | JS-002 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Hypertriglyceridemia; Atherosclerosis; Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias | Details |
| Ebronucimab | AK-102 | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd, Yabao Us Pharmaceutical Co Ltd | Homozygous familial hypercholesterolemia; Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipidemia, Familial Combined | Details |
| NNC0385-0434 | NNC0385-0434 | Phase 2 Clinical | Novo Nordisk A/S | Plaque, Atherosclerotic; Diabetes Mellitus, Type 2; Hypercholesterolemia; Renal Insufficiency, Chronic; Arteriosclerosis | Details |
| MIL-86 | MIL-86 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
| MK-0616 | MK-0616 | Phase 1 Clinical | Merck Sharp & Dohme Corp | Kidney Diseases | Details |
| Lerodalcibep | LIB-003 | Phase 3 Clinical | Lib Therapeutics | Atherosclerosis; Hypercholesterolemia; Stroke; Heterozygous familial hypercholesterolemia; Arteriosclerosis; Hyperlipoproteinemia Type II | Details |
This web search service is supported by Google Inc.
A-Z
